<p>Cybin Inc. has released a corporate presentation highlighting progress in its development of novel serotonergic agonists for mental health conditions. The company is advancing two proprietary clinical programs, HLP003 and HLP004, targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD), both of which have shown positive Phase 2 safety and efficacy results. The lead program, HLP003, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 studies for adjunctive treatment of MDD. Cybin reports a strong intellectual property portfolio with over 100 granted patents and more than 250 patent applications pending. The company’s cash position stands at US$83.8 million as of September 30, 2025. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on January 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Cybin Inc. Showcases Breakthrough Serotonergic Drug Pipeline for Depression and Anxiety